ceftazidime + cefotaxime + meropenem + vancomycin

This antibiotic regimen, consisting of ceftazidime, cefotaxime, meropenem, and vancomycin, is utilized as a supportive antibacterial therapy in the management of patients with enterocutaneous fistulas (ECF), particularly those exhibiting signs of systemic sepsis or local inflammation. The regimen was specifically documented in clinical trials conducted at Jinling Hospital, China, evaluating the efficacy of fibrin glue in low-output ECF. Ceftazidime and cefotaxime are third-generation cephalosporins, meropenem is a carbapenem, and vancomycin is a glycopeptide; together, they provide broad-spectrum coverage against Gram-positive and Gram-negative bacteria by inhibiting bacterial cell wall synthesis. The regimen is typically administered intravenously to manage infection-related complications that can hinder fistula closure.

Other names

ceftazidime + cefotaxime + meropenem + vancomycin-Jinling Hospital, China-enterocutaneous fistulaAntibiotics (ceftazidime, cefotaxime, or meropenem, with or without vancomycin)